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ABSTRACT
Pseudohypoparathyroidism (PHP) is a rare group of disorders characterised by end-organ 
resistance to the parathyroid hormone (PTH). A 16-year-old boy presented with a 2-year history 
of involuntary dystonic movements involving mainly the left hand, initially after writing and later 
during physical exercise. Serum calcium was 1.37 mmol/L (2.20–2.69), phosphate 2.1 mmol/L 
(0.8–1.45) and PTH 302 ng/L (12–88). CT scan of the head demonstrated multiple subcortical and 
diffuse basal ganglia calcifications. Genetic analysis confirmed a methylation defect in the GNAS 
cluster on chromosome 20q13.32 which established the diagnosis. Treatment with calcitriol and 
calcium carbonate led to complete remission of symptoms. Causes of hypocalcaemia should 
be considered in evaluating patients with movement disorders. The diagnosis of PHP-1B is 
challenging but the overall prognosis is excellent.
Abbreviations: PHP: pseudohypoparathyroidism; PTH: parathyroid hormone; PHP-
1A: pseudohypoparathyroidism type 1A; PHP-1B: pseudohypoparathyroidism type 1B; 
AHO: Albright’s hereditary osteodystrophy; DMRs: different methylated regions; PPHP: 
pseudopseudohypoparathyroidism
Introduction
Pseudohypoparathyroidism (PHP) is an heterogeneous 
group of disorders characterised by hypocalcaemia and 
hyperphosphataemia resulting from end-organ resist-
ance to parathyroid hormone (PTH) [1–9]. It is a rare 
disease with an estimated prevalence worldwide of 
approximately 7.9 cases per million [1,8].
The primary effect of PTH on the kidney is to increase 
calcium absorption from the distal tubules and the thick 
ascending limb of the loop of Henle and to inhibit phos-
phate reabsorption at the proximal tubule level. PTH is 
also responsible for mobilising calcium and phosphate 
from bone deposits into the circulation [1,2].
In PHP, PTH resistance occurs only at the renal 
proximal tubule level, representing an unusual form 
of hormone resistance [1,9,10]. The molecular defect 
responsible for most types of PHP affects the α-subunit 
of the stimulatory G-protein, which is downstream of 
many different G protein-coupled hormone receptors, 
rather than the PTH receptor itself [9–12]. PHP is part of 
a group of rare diseases associated with genetic disrup-
tion of imprinting genes, a phenomenon that restricts 
gene expression in either the paternally or maternally 
delivered gene copy [13].
Two main types of PHP have been described: PHP 
type 1A (PHP-1A) and 1B (PHP-1B). Patients with PHP-1A 
present with additional hormone resistance (including 
resistance to thyroid stimulating hormone and gonado-
tropin) as well as with Albright’s hereditary osteodystro-
phy (AHO), a constellation of features comprising short 
stature, obesity, round facies, brachydactyly, ectopic 
ossifications and/or mental retardation [1,9,10,14].
Pseudohypoparathyroidism type 1B is character-
ised by an absence of AHO features and renal resist-
ance to PTH, and, although initially no resistance to 
other hormones had been documented, recent reports 
have shown that other hormonal actions may also be 
impaired such as thyroid stimulating hormone [10,15–
18]. PHP-1B is most often a sporadic disorder, but sex-in-
fluenced autosomal dominant inheritance has been 
reported [13].
Since parathyroid action is only affected at the renal 
proximal tubule level, some individuals are asympto-
matic and may show only mild elevation of PTH as evi-
dence of hormone resistance [2,10,11,14]. However, at 
some point, most patients present with hypocalcaemia 
and develop symptoms such as tetany, muscle spasms 
or even seizures [2,5,11].
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calcifications in the frontal, parietal and occipital areas 
as well as diffuse bilateral thalamic and basal ganglia 
calcifications (Figure 1). Renal ultrasound demonstrated 
normal cortical-medullar differentiation with bilateral 
central millimetric lithiasis. The PTH level was 302 ng/L 
(12–88), 1,25-dyhydroxyvitamin D level 101.6  pmol/L 
(48.9–135.5) and 25-hydroxyvitamin D level 89.25 nmol/L 
(50.0–102.5). Because of the clinical suspicion of PHP, 
genetic analysis was performed which identified a defect 
in the GNAS cluster on chromosome 20q13.32 with loss 
of the imprinting at the A/B methylated promoter region. 
No deletion in the STX16 region (upstream of the GNAS 
cluster) was detected.
He was commenced on intravenous calcium gluco-
nate and oral calcitriol which was followed by progressive 
clinical and blood chemistry improvement. Complete 
remission of symptoms occurred when the total cal-
cium IV dose reached 4.5 g/day. After commencement 
of treatment, the patient did not experience any further 
paroxysmal movements and maintained a calcium level 
of 2.4 mmol/L and phosphate level of 1.1 mmol/L under 
therapy with calcitriol (0.75 μg/day) and oral calcium car-
bonate (12 g/day). Laboratory values (PTH, calcium and 
phosphate levels) returned to normal and a CT scan will 
be undertaken after 1 year of follow–up.
Discussion
A 16-year-old adolescent presented with tetany, mostly 
while practicing sport, and was found to have severe 
hypocalcaemia and hyperphosphataemia. Genetic analy-
sis demonstrated a methylation defect in the GNAS gene 
located on chromosome 20q13.32 (this complex locus 
encodes the α-subunit of the heterotrimeric G protein) 
confirming a diagnosis of PHP type 1B.
Parathroid hormone, via its Gsα-coupled receptor 
parathyroid hormone/parathyroid hormone-related 
peptide receptor (PTHR), is an important regulator of 
homoeostasis, maintaining blood calcium concentra-
tions within narrow limits. PTH stimulates the release of 
calcium and phosphate from the bone into the periph-
eral circulation, acts on the distal nephron increasing 
Case report
A 16-year-old boy was admitted to a general paediatric 
hospital for evaluation of an intermittent movement dis-
order. He had been healthy previously, except for a vesi-
coureteric reflux with no reported urinary tract infections 
since the age of 2 years. There was no consanguinity and 
no family history of movement or neurological disorders.
At the age of 14, he developed periods of mild joint 
pain (mostly in the wrists, knees and elbows) and also epi-
sodes of left-hand paralysis while writing, lasting 2–3 min 
and ceasing spontaneously. Episodes became more fre-
quent during the following 2 years. They occurred mostly 
during sports, about 20 min after beginning exercise, and 
were described as a dystonic posture of both hands and 
forearms. Episodes associated with emotional stress or 
infections also occurred, also of 3-min duration and with 
spontaneous cessation. In the month prior to evaluation, 
he complained of moderate fatigue, weakness and spo-
radic frontal headaches that responded to analgesics. 
No aura, dizziness, vertigo, trembling, dysarthria or other 
symptoms occurred.
For 2 years, no medical care was sought, and when 
he was 16 he was evaluated at a paediatric hospital. 
His weight was 51 kg (10th percentile), height 165 cm 
(10th–25th percentile), body mass index of 18.7 kg/m2 
(10th–25th percentile), pubertal development was 
Tanner stage 5 and physical including neurological exam-
ination was normal. Serum calcium was 1.37  mmol/L 
(2.20–2.69) and phosphate 2.1 mmol/L (0.8–1.45).
He was admitted to the Endocrine Unit of Hospital 
Dona Estefânia, Lisbon for further investigation and 
treatment.
Investigations
Haemoglobin, leucocyte and platelet count, liver and 
kidney function, sodium, potassium, magnesium and 
chloride levels were normal, as were thyroid function 
tests. The urinary calcium/creatinine ratio level was 
also normal. The electrocardiogram demonstrated 
peaked T-waves and no other abnormalities. Head com-
puted tomography (CT) showed multiple subcortical 
Figure 1. head ct demonstrating (a) multiple subcortical calcifications in frontal area, (B) basal ganglia and (c) in fronto-parietal 
areas.
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calcium reabsorption, and in the proximal tubule inhibits 
phosphate reabsorption and increases 1-α-hydroxylase 
synthesis. The latter stimulates the synthesis of biologi-
cally active 1.25 dihydroxyvitamin D, indirectly increasing 
intestinal calcium reabsorption [19,20].
The hallmark of PHP type 1B is the defect in the renal 
response to PTH owing to the abnormal G-protein func-
tion that occurs in renal proximal tubules but not in other 
sites of PTH action [19]. Defects in this signalling pathway 
result in PTH resistance and hyperphosphataemia. PTH 
anticalciuric action occurs in the distal nephron which is 
not affected in PHP-1B, which might explain why patients 
have normocalciuria [9,11].
The patient presented with normal urinary calcium 
levels but the renal ultrasound demonstrated millimetric 
lithiasis. Although lithiasis is not frequently described in 
PHP-1B, it is a common feature in other diseases with 
hyperphosphataemia, e.g. hypothyroidism, since high 
serum phosphate levels predispose to ectopic miner-
alisation and consequent kidney stone formation and 
nephrocalcinosis [21]. Although further studies are nec-
essary, in this patient the elevated serum phosphate 
might have been responsible for the renal lithiasis. 
Monitoring the evaluation over time is essential to assess 
whether regression of the latter is associated with nor-
malisation of phosphate.
Although the genetic mutation is sporadic, it may 
occasionally have an autosomal dominant transmis-
sion pattern. No clinical differences have been reported 
between the sporadic and the familial forms of PHP-1B 
[22]. In this report, since the patient had no siblings and 
the parents had no intention of having another child, no 
further familial genetic analysis was undertaken.
The heterozygous inactivating mutations involving 
GNAS exons cause different disorders. This is explained 
by genomic imprinting, an epigenetic phenomenon 
affecting a restricted number of genes by which one 
allele, either maternal or paternal, undergoes a partial 
or total loss of expression [9,11,13]. When the mutation 
occurs on the maternal allele, PHP-1A patients present 
with multihormonal resistance and AHO features. On the 
other hand, if an inactivating mutation is located on the 
paternal allele, patients will present with most of the AHO 
features but will not be obese or have neurocognitive 
impairment and usually no hormonal resistance, which 
is called pseudopseudohypoparathyroidism (PPHP) [23].
Unlike in PHP-1A, PHP-1B patients present with epige-
netic defects at one or more DMRs (different methylated 
regions) of the GNAS gene. Most cases of PHP-1B are 
sporadic and show loss of methylation at GNAS exons 
A/B, XL and AS. This patient had a loss of imprinting at the 
A/B methylated promoter region. In the few reports of 
autosomal dominant PHP-1B, there is a maternal delec-
tion either in GNAS or in STX16, which is associated with 
distinct methylation changes involving different GNAS 
exons [23].
Despite being congenital, only a few cases of PHP in 
the neonatal period have been reported [24]. Clinical 
manifestations typically occur later in childhood, sug-
gesting that PTH resistance and consequent changes in 
serum calcium and phosphate levels develop gradually. 
The mechanisms that maintain normal PTH signalling 
during early infancy remain obscure. Consistent with 
the literature, no symptoms were evident in this patient 
before the age of 14 years [14].
Intracranial calcifications, especially in the basal gan-
glia, have also been described [20]. Usually, these calcifica-
tions do not cause clinical complications and sometimes 
it is discovered accidentally and further investigation 
leads to the diagnosis of PHP in asymptomatic individuals.
This case demonstrates the importance of considering 
disorders of calcium metabolism in children presenting with 
movement abnormalities. In this patient, a dystonic posture 
was initially associated with repetitive tonic  movements 
such as writing and it was not until 2 years later that he 
became symptomatic during physical exercise. Causes 
of hypocalcaemia, including PHP-1B should always be 
 considered in patients with tetany, especially before inves-
tigation for a neurological cause of movement disorders.
PHP-1B is a treatable condition and the prognosis 
is excellent. Patients should be monitored annually for 
calcium, phosphate, PTH and urinary calcium levels. 
Although rarely, other endocrinal disorders may be 
present, so routine screening for abnormal thyroid and 
gonadotropin function should also be undertaken [14].
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